DKFZ-MOST Cooperation in Cancer Research – List of all projects Ca 92 – Ca 144

Project phase 01.01.2001 – 31.12.2003
Ca-.No 092  Identification of NKp46 ligand: A ligand which is involved in the lysis of tumor cells and virally infected cells by natural killer cells
Ca-.No 093  A biochemical and molecular genetic approach to study the role of hepatocyte nuclear factor 4 (HNF4) and suppression of tumor development by fatty acids
Ca-.No 094  Modulation of the interaction of KGF with its receptor in normal and tumor cells
Ca-.No 095  The functional relevance of alterations in integrin alpha6beta4 and protein kinase C regulation in human and mouse skin carcinogenesis
Ca-.No 096  Novel anti-cancer vaccines based on oral application of recombinant Salmonella typhimurium bacteria
Ca-.No 097  Expansion of human hematopoietic stem cells and megakaryocyte progenitors for transplantation in cancer patients

Project phase 01.07.2002 – 30.06.2005
Ca-.No 098  Phenotypic reversal in multidrug resistant cancer cells
Ca-.No 099  Targeting the adenosine A3 receptor for the treatment and prevention of colon carcinoma: molecular mechanisms and preclinical evaluation
Ca-.No 100  The CD95 (APO-1/Fas) death system in tumor progression
Ca-.No 101  Involvement of c-Abl in HPV-induced carcinogenesis
Ca-.No 102  Tyrosine kinase VEGF receptors and neuropilins and the role of their VEGF and semaphoring ligands in tumor development and progression
Ca.-No 103  Human papillomavirus type 16 in cervical cancer: the potential role of E6 natural variants in regression of progression of viral-induced disease
Ca.-No 104  Functional significance of insulin signaling in skin and skin tumorigenesis
Ca.-No 105  Macromolecular polymers as a novel platform for the tumor directed delivery of drugs targeting molecular processes of apoptosis and radiation

Phase IX 01.01.2004 – 31.12.2006
Ca.-No 106  Identification of the genetic network controlled by the caudal transcriptional regulator
Ca.-No 107  The role of nuclear lamina proteins in organizing nuclear architecture in normal and transformed cells
Ca.-No 108  Influence of antigen receptor mediated signaling in apoptosis and survival during the selection of lymphocytes
Ca.-No 109  Functional and physical analysis of the IGF-I receptor gene in progression to advanced breast cancer
Ca.-No 110  Chromosomal fragile sites and cancer
Ca.-No 111  Oncogenic activity of HTLV-I Tax and its prevention
Ca.-No 112  Tumor-associated blood vessel endothelium as a barrier to infiltration of effector immunocytes

01.07.2004 – 31.12.2005
Ca.-No 113  Genotypes of drug transporting and metabolising genes as potential modifiers of cancer risk and chemotherapy-sensitivity
Ca.-No 114  New strategies in the treatment of osteolytic bone metastasis of mammary carcinoma
Ca.-No 115  The impact of host and tumor derived IL-1 on tumor growth and host defense
Ca.-No 116  Melanoma growth, anti-tumor immune response and inflammation: a critical three-lateral interrelationship for successful immunotherapy
Ca.-No 117  Molecular mechanisms driving HCC development in mouse model of hepatitis-associated cancer
Ca.-No 118  Evaluation of function for ligands of activating natural killer cells receptors in anti-tumor immunity
Ca.-No 119  Analysis of Alu exonization and alternative splicing in cancer genes
Ca.-No 120  Identification and functional analysis of protein phosphorylation and dephosphorylation in the ATM-mediated DNA damage response

Phase IX 01.01.2007 – 31.12.2009
Ca.-No 121  Hypomethylation-induced genetic instability as a factor in tumor formation
Ca.-No 122  Epigenetic mechanisms regulating transcriptions and genome stability in cancer cells
Ca.-No 123  Contribution of endoplasmic reticulum (ER) stress and mitochondrial perturbation in the death of breast and colon cancer cells induced by plant cytotoxic agents
Ca.-No 124  The role of DNA damage-mediated BID phosphorylation for TRAIL-induced apoptosis
Ca.-No 125  Identification and characterization of cytokinetic targets in cancer therapy
Ca.-No 126  High resolution assessment of antiogenesis and normalization of tumor vessel phenotype under therapy using implanted MR-coils and functional and molecular MR-imaging methods
Ca.-No 127  Human heparanase – a promising target for the development of therapeutic strategies in cancer

Phase X 01.07.2008 – 30.06.2011
Ca.-No 128  Inflammation-dependent immunosuppressive tumor microenvironment: Its neutralization for successful tumor immunotherapy
Ca.-No 129  Intracellular signalling pathways controlling cell fate decisions of lymphocytes during differentiation and tumorigenesis
Ca.-No 130  Molecular mechanisms of inflammation induced liver cancer
Ca.-No 131  Molecular pathways underlying apoptotic and non apoptotic cell death and their implication in cancer development
Ca.-No 132  Interplay between VEGF and angiopoietins in the vascular tumor microenvironment
Ca.-No 133  Exploring the network of STAT3 and MITF in melanoma using RNAi libraries
Ca.-No 134  The Cellular pathways leading to cancer

Phase X 01.07.2009 – 30.06.2012
Ca.-No 135  Regulation and function of viral and cellular microRNAs controlling the immune response
Ca.-No 136  Monochlonal antibodies targeting CD24 in the treatment of pancreatic cancer
Ca.-No 137  Regulation of p53 family tumor suppressors under DNA damage stress
Ca.-No 138  The complex interactions of semaphorins and the delta-notch pathway in tumor angiogenesis
Ca.-No 139  Defining control and function of alternative splicing during tumorigenesis

Phase X 01.07.2010 – 30.06.2013
Ca.-No 140  RTK-dependent cell death in pediatric tumors of neural origin
Ca.-No 141  The roles of SIL(STIL) in centrosome biology – relevance to cancer and developmental disorders
Ca.-No 142  Characterization and regulation of NCR and NKG2D ligands in cancer
Ca.-No 143  Interactions between cancer associated fibroblasts (CAFs) and myeloid-derived inflammatory cells in the dynamic phenotype of the microenvironment during tumor progression; basic mechanisms and preclinical applications of novel intervention strategies
Ca.-No 144  Heparanase: a promising target and tumor antigen for therapeutic strategies in cancer

to top